Patients battling with kidney cancer can now breathe a sigh of relief.
A new wonder drug, Nivolumab is helping patients with terminal cancer to live extra six to seven years.
The treatment, which is a form of immunotherapy, targets kidney cancer (usually difficult to treat) and teaches the body to attack tumours.
A research by the Royal Marsden Hospital (London, the United Kingdom) show that patients can now live an average of 5.4 months longer on nivolumab than on standard treatment. The study was done on 821 patients around the world, of whom 40 were based at the London hospital.
There is downside to it though, the drug doesn’t work on all patients.